
Opinion|Videos|July 29, 2024
Current Approach for Treating Anemia in LR-MDS
Author(s)Guillermo Garcia-Manero, MD
A medical oncologist outlines approaches to treating anemia in patients with lower-risk myelodysplastic syndromes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is your current approach for treating anemia in LR-MDS?
- When would you choose ESAs for first-line treatment?
- When would you switch therapies? Would you dose escalate before switching to an EMA (e.g. second-line)?
- What factors lead to a decision to use luspatercept as a first-line treatment?
- When do you dose escalate?
- When do you dose escalate?
- When would you choose ESAs for first-line treatment?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















